Literature DB >> 7813311

Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.

M Nootens1, B Schrader, E Kaufmann, R Vestal, W Long, S Rich.   

Abstract

Vasodilators have been a main focus of therapy for primary pulmonary hypertension. Adenosine and prostacyclin have been shown to reduce pulmonary vascular resistance acutely in these patients. In order to compare the acute hemodynamic effects of adenosine and prostacyclin, ten patients with severe primary pulmonary hypertension, unresponsive to medical therapy, were studied. After baseline hemodynamics were obtained, an adenosine infusion, 50 to 100 ng/kg/min, was begun and titrated to the maximum tolerated dose. Hemodynamics were allowed to return to baseline, and thereafter, a prostacyclin infusion was begun at 2 ng/kg/min, and titrated to the maximum tolerated dose. Overall, adenosine (200 +/- 53 ng/kg/min) produced a 33 +/- 18% (p < 0.001) fall in pulmonary vascular resistance and a 52 +/- 25% (p < 0.001) increase in cardiac output with no effect on pulmonary or systemic arterial pressures. Prostacyclin (8 +/- 4 ng/kg/min) caused a 22 +/- 18% (p < 0.01) fall in pulmonary vascular resistance and a 25 +/- 26% (p < 0.05) increase in cardiac output with a 14 +/- 6% (p < 0.001) decrease in systemic arterial pressure, but no change in pulmonary arterial pressure. The effects of adenosine and prostacyclin on pulmonary vascular resistance were similar (r = 0.70, r2 = 0.49, p = 0.02). Adenosine and prostacyclin have similar hemodynamic effects acutely in primary pulmonary hypertension. Adenosine may be useful as a test of the potential for long-term prostacyclin therapy in patients with primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7813311     DOI: 10.1378/chest.107.1.54

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  Pulmonary hypertension: its assessment and treatment.

Authors:  S Brij; A J Peacock
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Cor Pulmonale.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 4.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

Authors:  Darren B Taichman; Joe Ornelas; Lorinda Chung; James R Klinger; Sandra Lewis; Jess Mandel; Harold I Palevsky; Stuart Rich; Namita Sood; Erika B Rosenzweig; Terence K Trow; Rex Yung; C Gregory Elliott; David B Badesch
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

5.  Phase I safety study of ranolazine in pulmonary arterial hypertension.

Authors:  Mardi Gomberg-Maitland; Robert Schilz; Anuj Mediratta; Karima Addetia; Sandra Coslet; Vasiliki Thomeas; Hunter Gillies; Ronald J Oudiz
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 6.  Approach to pulmonary hypertension.

Authors:  G L Yung; L J Rubin
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

7.  Minimally invasive and alternative approaches for long-term LVAD placement: the Vanderbilt strategy.

Authors:  Simon Maltais; Mary E Davis; Nicholas Haglund
Journal:  Ann Cardiothorac Surg       Date:  2014-11

Review 8.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

9.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

Authors:  T Thenappan; S J Shah; S Rich; L Tian; S L Archer; M Gomberg-Maitland
Journal:  Eur Respir J       Date:  2009-12-23       Impact factor: 16.671

10.  A randomized pilot study on the effect of niacin on pulmonary arterial pressure.

Authors:  Martin J McNamara; Jason J Sayanlar; Daniel J Dooley; Monvadi B Srichai; Allen J Taylor
Journal:  Trials       Date:  2015-11-21       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.